Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Leuprolide · Eligard, Fensolvi

Peptide · Agonist of gonadotropin-releasing hormone receptor (GNRHR) · developed by Abbvie Endocrine

Approved FDA, Apr 1985
1 Registered trials

What is Leuprolide?

Leuprolide is a synthetic nonapeptide analogue of gonadotropin-releasing hormone that binds GnRH receptors. Continuous administration desensitizes pituitary GnRH receptors, reducing FSH and LH secretion and suppressing testicular and ovarian steroid production. It is studied in early breast cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Eligard, Fensolvi, Lupron Depot, Vabrinty
Drug type
Peptide
Targets
gonadotropin-releasing hormone receptor (GNRHR)
Mechanism
Agonist of gonadotropin-releasing hormone receptor (GNRHR)
Pathways
pituitary gonadotropin (FSH and LH) secretion, testicular and ovarian steroidogenesis
Therapy area
Oncology
Developer
Abbvie Endocrine Inc
In trials of
NVS
FDA status
Approved as Eligard, Fensolvi, Lupron Depot (April 9, 1985), NDA019010 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Apr 30, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05827081 Phase 3 Early Breast Cancer Active not recruiting NVS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Early Breast Cancer

Other drugs acting on GNRHR

Sources

Updated Oct 25, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.